185 related articles for article (PubMed ID: 32557810)
1. Anagrelide influences thrombotic risk, and prolongs progression-free and overall survival in essential thrombocythaemia vs hydroxyurea plus aspirin.
Kellner A; Dombi P; Illes A; Demeter J; Homor L; Ercsei I; Simon Z; Karadi E; Herczeg J; Gy Korom V; Gasztonyi Z; Szerafin L; Udvardy M; Egyed M
Eur J Haematol; 2020 Oct; 105(4):408-418. PubMed ID: 32557810
[TBL] [Abstract][Full Text] [Related]
2. Anagrelide reduces thrombotic risk in essential thrombocythaemia vs. hydroxyurea plus aspirin.
Dombi P; Illés Á; Demeter J; Homor L; Simon Z; Karadi E; Udvardy M; Egyed M
Eur J Haematol; 2017 Feb; 98(2):106-111. PubMed ID: 27557754
[TBL] [Abstract][Full Text] [Related]
3. Hydroxyurea compared with anagrelide in high-risk essential thrombocythemia.
Harrison CN; Campbell PJ; Buck G; Wheatley K; East CL; Bareford D; Wilkins BS; van der Walt JD; Reilly JT; Grigg AP; Revell P; Woodcock BE; Green AR;
N Engl J Med; 2005 Jul; 353(1):33-45. PubMed ID: 16000354
[TBL] [Abstract][Full Text] [Related]
4. [Treatment outcome of patients with essential thrombocythemia at our department in Hungary].
Iványi JL; Marton É; Plander M; Szendrei T
Orv Hetil; 2016 Feb; 157(9):336-41. PubMed ID: 26895801
[TBL] [Abstract][Full Text] [Related]
5. [An audit of the Hungarian Philadelphia negative chronic myeloproliferative neoplasia registry. Evaluation of the essential thrombocythaemic patients].
Dombi P; Illés Á; Demeter J; Homor L; Simon Z; Udvardy M; Karádi É; Kellner Á; Egyed M
Orv Hetil; 2017 Jan; 158(3):111-116. PubMed ID: 28110571
[TBL] [Abstract][Full Text] [Related]
6. Anagrelide compared with hydroxyurea in essential thrombocythemia: a meta-analysis.
Samuelson B; Chai-Adisaksopha C; Garcia D
J Thromb Thrombolysis; 2015 Nov; 40(4):474-9. PubMed ID: 25894476
[TBL] [Abstract][Full Text] [Related]
7. Anagrelide: a review of its use in the management of essential thrombocythaemia.
Wagstaff AJ; Keating GM
Drugs; 2006; 66(1):111-31. PubMed ID: 16398570
[TBL] [Abstract][Full Text] [Related]
8. Anagrelide: new drug. Essential thrombocythaemia: further evaluation needed for this last-resort treatment.
Prescrire Int; 2006 Jun; 15(83):83-6. PubMed ID: 16764090
[TBL] [Abstract][Full Text] [Related]
9. [The effectiveness of anagrelide treatment in patients with Ph negative myeloproliferative diseases: influence on the incidence of thrombosis in the data from the Registry of patients with essential thrombocythemia and thrombocythemia associated with other myeloproliferative diseases treated with Thromboreductin® to the end of 2012].
Penka M; Schwarz J; Ovesná P; Cervinek L; Dulíček P; Pospíšilová D; Kissová J; Pavlík T;
Vnitr Lek; 2013 Jun; 59(6):516-31. PubMed ID: 23808749
[TBL] [Abstract][Full Text] [Related]
10. Cardiovascular Safety of Anagrelide Hydrochloride versus Hydroxyurea in Essential Thrombocythaemia.
Gotic M; Egyed M; Gercheva L; Warzocha K; Kvasnicka HM; Achenbach H; Wu J
Cardiovasc Toxicol; 2021 Mar; 21(3):236-247. PubMed ID: 33123978
[TBL] [Abstract][Full Text] [Related]
11. Anagrelide compared with hydroxyurea in WHO-classified essential thrombocythemia: the ANAHYDRET Study, a randomized controlled trial.
Gisslinger H; Gotic M; Holowiecki J; Penka M; Thiele J; Kvasnicka HM; Kralovics R; Petrides PE;
Blood; 2013 Mar; 121(10):1720-8. PubMed ID: 23315161
[TBL] [Abstract][Full Text] [Related]
12. Anagrelide in Essential Thrombocythemia (ET): Results from 150 patients over 25 years by the "Ph1-negative Myeloproliferative Neoplasms Latium Group".
Mazzucconi MG; Baldacci E; Latagliata R; Breccia M; Paoloni F; Di Veroli A; Cedrone M; Anaclerico B; Villivà N; Porrini R; Montefusco E; Andriani A; Montanaro M; Scaramucci L; Spadea A; Rago A; Cimino G; Spirito F; Santoro C
Eur J Haematol; 2020 Sep; 105(3):335-343. PubMed ID: 32441419
[TBL] [Abstract][Full Text] [Related]
13. Decreased survival and increased rate of fibrotic progression in essential thrombocythemia chronicled after the FDA approval date of anagrelide.
Tefferi A; Szuber N; Vallapureddy RR; Begna KH; Patnaik MM; Elliott MA; Christopher Hook C; Wolanskyj AP; Hanson CA; Ketterling RP; Pardanani A; Gangat N
Am J Hematol; 2019 Jan; 94(1):5-9. PubMed ID: 30252953
[TBL] [Abstract][Full Text] [Related]
14. [Efficacy and safety of anagrelide in treatment of essential thrombocythemia: multicenter, randomized controlled clinical trial].
Ge X; Yang L; Jin J; Qian W; Li J; Yang R; Cao X; Jiang B; Wang Z; Hou M; Zhang W; Xiao Z; Zhao Y; Gao D; Zhang X; Wang S; Sun A; Fu J; Su L; Li K
Zhonghua Xue Ye Xue Za Zhi; 2015 Jul; 36(7):547-52. PubMed ID: 26304075
[TBL] [Abstract][Full Text] [Related]
15. [Anagrelide in the treatment of thrombocythemia essential (ET)].
Mazur G; Wróbel T; Podolak-Dawidziak M; Kuliszkiewicz-Janus M; Potoczek S; Nosol J; Kuliczkowski K
Pol Arch Med Wewn; 2004 Dec; 112(6):1445-50. PubMed ID: 15962609
[TBL] [Abstract][Full Text] [Related]
16. Impact of Hydroxyurea on Survival and Risk of Thrombosis Among Older Patients With Essential Thrombocythemia.
Podoltsev NA; Zhu M; Zeidan AM; Wang R; Wang X; Davidoff AJ; Huntington SF; Giri S; Gore SD; Ma X
J Natl Compr Canc Netw; 2019 Mar; 17(3):211-219. PubMed ID: 30865915
[TBL] [Abstract][Full Text] [Related]
17. Anagrelide: what was new in 2004 and 2005?
Petrides PE
Semin Thromb Hemost; 2006 Jun; 32(4 Pt 2):399-408. PubMed ID: 16810615
[TBL] [Abstract][Full Text] [Related]
18. Antiplatelet drugs for polycythaemia vera and essential thrombocythaemia.
Squizzato A; Romualdi E; Passamonti F; Middeldorp S
Cochrane Database Syst Rev; 2013 Apr; (4):CD006503. PubMed ID: 23633335
[TBL] [Abstract][Full Text] [Related]
19. Thrombosis in thrombocythemic Ph- myeloproliferations is associated with higher platelet count prior to the event: results of analyses of prothrombotic risk factors from a registry of patients treated with anagrelide.
Schwarz J; Ovesná P; Černá O; Kissová J; Maaloufová Soukupová J; Brychtová Y; Doubek M; Červinek L; Cmunt E; Dulíček P; Campr V; Křen L; Penka M;
Eur J Haematol; 2016 Jan; 96(1):98-106. PubMed ID: 25807961
[TBL] [Abstract][Full Text] [Related]
20. Management of refractory essential thrombocythemia with anagrelide in a patient undergoing hemodialysis.
Mesquita Mdo C; Sol EB; Malarme M; Noubouossie D; Demulder AC
Clin Ther; 2009 Nov; 31(11):2559-64. PubMed ID: 20110000
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]